Evidence map›Paper›PMID 38457357›Full record

ArticleBlood2024

Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT.

Maria E Bernabéu-Herrero, Dilipkumar Patel, Adrianna Bielowka, JiaYi Zhu, Kinshuk Jain, Ian S Mackay, Patricia Chaves Guerrero, Giulia Emanuelli, Luca Jovine, Michela Noseda and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Hereditary haemorrhagic telangiectasia.Nature reviews. Disease primers · 2025
    Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Maria E Bernabéu-HerreroNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Dilipkumar PatelNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Adrianna BielowkaNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
JiaYi ZhuCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Kinshuk JainNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0001-7903-3005
Ian S MackayEar, Nose and Throat Surgery, Charing Cross and Royal Brompton Hospitals, London, United Kingdom.ORCID 0009-0002-2158-3068
Patricia Chaves GuerreroNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0003-1364-0130
Giulia EmanuelliCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8899-6110
Luca JovineDepartment of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0002-2679-6946
Michela NosedaNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Stefan J MarciniakCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8472-7183
Micheala A AldredDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-7390-9181
Claire L ShovlinNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0001-9007-5775
NIHR Imperial Biomedical Research Centre · GBUniversity of Cambridge · GBImperial College London · GBImperial College Healthcare NHS Trust · GBIndiana University School of MedicineKarolinska Institutet · SERoyal Brompton Hospital · GB

Funding

Genomics of Pulmonary Vascular DiseaseR35HL140019 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ALDRED, MICHEALA A · 2018 to 2024
$5.6M
NHLBI NIH HHS R35 HL140019
6 · The paper itself

Abstract

abstractFor monogenic diseases caused by pathogenic loss-of-function DNA variants, attention focuses on dysregulated gene-specific pathways, usually considering molecular subtypes together within causal genes. To better understand phenotypic variability in hereditary hemorrhagic telangiectasia (HHT), we subcategorized pathogenic DNA variants in ENG/endoglin, ACVRL1/ALK1, and SMAD4 if they generated premature termination codons (PTCs) subject to nonsense-mediated decay. In 3 patient cohorts, a PTC-based classification system explained some previously puzzling hemorrhage variability. In blood outgrowth endothelial cells (BOECs) derived from patients with ACVRL1+/PTC, ENG+/PTC, and SMAD4+/PTC genotypes, PTC-containing RNA transcripts persisted at low levels (8%-23% expected, varying between replicate cultures); genes differentially expressed to Bonferroni P < .05 in HHT+/PTC BOECs clustered significantly only to generic protein terms (isopeptide-bond/ubiquitin-like conjugation) and pulse-chase experiments detected subtle protein maturation differences but no evidence for PTC-truncated protein. BOECs displaying highest PTC persistence were discriminated in unsupervised hierarchical clustering of near-invariant housekeeper genes, with patterns compatible with higher cellular stress in BOECs with >11% PTC persistence. To test directionality, we used a HeLa reporter system to detect induction of activating transcription factor 4 (ATF4), which controls expression of stress-adaptive genes, and showed that ENG Q436X but not ENG R93X directly induced ATF4. AlphaFold accurately modeled relevant ENG domains, with AlphaMissense suggesting that readthrough substitutions would be benign for ENG R93X and other less rare ENG nonsense variants but more damaging for Q436X. We conclude that PTCs should be distinguished from other loss-of-function variants, PTC transcript levels increase in stressed cells, and readthrough proteins and mechanisms provide promising research avenues.

Indexed as

Activin Receptors, Type IICodon, NonsenseEndoglinTelangiectasia, Hereditary HemorrhagicEndothelial CellsFemaleHumansMaleMutationNonsense Mediated mRNA DecaySmad4 ProteinActivin Receptors, Type IIACVRL1 protein, humanCodon, NonsenseEndoglinENG protein, humanSmad4 ProteinSMAD4 protein, human

Identifiers

PMID38457357
PMCPMC11181359
OpenAlexW4392616748

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.